Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.

Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, Abreu M, Elkind R, Fehn K, de Castro A, Wang Y, Derman O, Nelson R, Uehlinger J, Gritsman K, Sica RA, Kornblum N, Mantzaris I, Shastri A, Janakiram M, Goldfinger M, Verma A, Braunschweig I, Bachier-Rodriguez L.

J Hematol Oncol. 2020 Jan 3;13(1):1. doi: 10.1186/s13045-019-0838-y.

2.

Twist of Fate for Acute Promyelocytic Leukemia: TRIB3-TWIST1 Interaction Promotes Resistance.

Peeke SZ, Gritsman K.

Clin Cancer Res. 2019 Oct 15;25(20):6018-6020. doi: 10.1158/1078-0432.CCR-19-2140. Epub 2019 Aug 12.

PMID:
31405833
3.

FLT3-ITD gets by with a little help from PRMT1.

Gritsman K.

Blood. 2019 Aug 8;134(6):498-500. doi: 10.1182/blood.2019001876. No abstract available.

4.

Signaling Pathways in Leukemic Stem Cells.

Gurska LM, Ames K, Gritsman K.

Adv Exp Med Biol. 2019;1143:1-39. doi: 10.1007/978-981-13-7342-8_1. Review.

PMID:
31338813
5.

PI3 kinase alpha and delta promote hematopoietic stem cell activation.

Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe RO, Ames K, Ostrodka L, Haque T, Kaur I, Mills TS, Agarwal A, Pietras EM, Zhao JJ, Roberts TM, Gritsman K.

JCI Insight. 2019 May 23;5. pii: 125832. doi: 10.1172/jci.insight.125832.

6.

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.

Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S, Verma A, Ye BH, Janakiram M.

Blood. 2018 Oct 4;132(14):1507-1518. doi: 10.1182/blood-2018-01-824607. Epub 2018 Aug 13.

7.

IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U.

J Exp Med. 2018 Jun 4;215(6):1709-1727. doi: 10.1084/jem.20180147. Epub 2018 May 17.

8.

Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia.

Darbinyan K, Shastri A, Budhathoki A, Helbig D, Snyder R, Pradhan K, Saleh-Esa J, Kornblum NS, Binder AF, Goel S, Janakiram M, Derman O, Gritsman K, Steidl U, Braunschweig I, Verma A, Mantzaris I.

Blood Adv. 2017 Oct 26;1(24):2120-2123. doi: 10.1182/bloodadvances.2017007013. eCollection 2017 Nov 14.

9.

Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells.

Hemmati S, Haque T, Gritsman K.

Front Oncol. 2017 Nov 13;7:265. doi: 10.3389/fonc.2017.00265. eCollection 2017. Review.

10.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

11.

A myeloid tumor suppressor role for NOL3.

Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, Steidl U.

J Exp Med. 2017 Mar 6;214(3):753-771. doi: 10.1084/jem.20162089. Epub 2017 Feb 23.

12.

Control of the innate immune response by the mevalonate pathway.

Akula MK, Shi M, Jiang Z, Foster CE, Miao D, Li AS, Zhang X, Gavin RM, Forde SD, Germain G, Carpenter S, Rosadini CV, Gritsman K, Chae JJ, Hampton R, Silverman N, Gravallese EM, Kagan JC, Fitzgerald KA, Kastner DL, Golenbock DT, Bergo MO, Wang D.

Nat Immunol. 2016 Aug;17(8):922-9. doi: 10.1038/ni.3487. Epub 2016 Jun 6.

13.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
14.

A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.

Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ.

Nat Commun. 2015 Oct 7;6:8501. doi: 10.1038/ncomms9501.

15.

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R.

Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14.

16.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U.

Blood. 2015 Aug 27;126(9):1118-27. doi: 10.1182/blood-2014-12-618801. Epub 2015 Jul 13.

17.

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.

Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA.

Nat Med. 2015 Jan;21(1):71-5. doi: 10.1038/nm.3751. Epub 2014 Dec 8.

18.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ.

J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.

19.

Akt: a double-edged sword for hematopoietic stem cells.

Kharas MG, Gritsman K.

Cell Cycle. 2010 Apr 1;9(7):1223-4. Epub 2010 Apr 1. No abstract available.

PMID:
20234178
20.

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K.

Blood. 2010 Feb 18;115(7):1406-15. doi: 10.1182/blood-2009-06-229443. Epub 2009 Dec 14.

21.

Nodal signaling patterns the organizer.

Gritsman K, Talbot WS, Schier AF.

Development. 2000 Mar;127(5):921-32.

22.

Conserved requirement for EGF-CFC genes in vertebrate left-right axis formation.

Yan YT, Gritsman K, Ding J, Burdine RD, Corrales JD, Price SM, Talbot WS, Schier AF, Shen MM.

Genes Dev. 1999 Oct 1;13(19):2527-37.

23.

Mouse Lefty2 and zebrafish antivin are feedback inhibitors of nodal signaling during vertebrate gastrulation.

Meno C, Gritsman K, Ohishi S, Ohfuji Y, Heckscher E, Mochida K, Shimono A, Kondoh H, Talbot WS, Robertson EJ, Schier AF, Hamada H.

Mol Cell. 1999 Sep;4(3):287-98.

24.

The EGF-CFC protein one-eyed pinhead is essential for nodal signaling.

Gritsman K, Zhang J, Cheng S, Heckscher E, Talbot WS, Schier AF.

Cell. 1999 Apr 2;97(1):121-32.

25.

Supplemental Content

Loading ...
Support Center